BSEM BioStem Technologies Inc

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

The presentation will be webcast at 1:30 PM ET on April 10, 2025

POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that its Chief Executive Officer, Jason Matuszewski, will present at the 24th Annual Needham Virtual Healthcare Conference at 1:30 PM ET on Thursday, April 10, 2025. Management will also be hosting investor meetings during the conference.

BioStem Technologies Presentation Access:

  • Presenter: Jason Matuszewski, Chief Executive Officer
  • Date: Thursday, April 10, 2025
  • Time: 1:30 PM ET
  • Webcast Link & Archive:
  • 1-on-1 Meeting Request:

Join BioStem’s Distribution List & Social Media:

To follow the latest developments at BioStem, sign-up to the Company’s email distribution list , and follow us on and .

About BioStem Technologies, Inc. (OTC: BSEM):

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain®processing method. BioREtain®has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.

For more information visit and follow us on and .

BioStem Technologies, Inc.

Phone: 954-380-8342

Website: E-Mail: X: Facebook:

Investor Relations

Adam Holdsworth

917-497-9287



EN
27/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioStem Technologies Inc

 PRESS RELEASE

BioStem Technologies Reports Positive Top-Line Clinical Results Demons...

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers Randomized controlled trial results published in the International Journal of Tissue Repair demonstrate BioRetain® allografts significantly improve probability of achieving lasting wound closure versus standard of care POMPANO BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...

 PRESS RELEASE

BioStem Technologies to Host Third Quarter 2025 Financial Results Conf...

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025 Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announces it will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the quarter from...

 PRESS RELEASE

BioStem Technologies Appoints KPMG as its Independent Registered Publi...

BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the Audit Committee of its Board of Directors has approved the appointment of KPMG LLP (“KPMG”) as the Company's independent registered public accounting firm, and it has ended its engagement with its prior registered independent public accounting firm, Marcum...

 PRESS RELEASE

BioStem Technologies Expands Partnership with the Florida Panthers as ...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program Program has honored more than 500 members of the military since its inceptionSponsorship honors both local military veterans and healthcare professionals POMPANO BEACH, Fla., Oct. 02, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, and the , announced today that they will celebrate the 13th season of the “” program through...

 PRESS RELEASE

BioStem Showcasing its Leading BioREtain® Technology at the Symposium ...

BioStem Showcasing its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting Company co-exhibiting with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three scientific posters feature BioStem’s proprietary allograft portfolio POMPANO BEACH, Fla., Sept. 05, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced its agenda for the Symposium for A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch